Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721453 | 0.91 | MAPT (0.46) | MAPTCHEK1ALOX5SMN1; SMN2CYP1A2 | |
| SCHEMBL1920686 | 0.87 | ALDH1A1 (0.44) | MAPTCHEK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL2451575 | 0.83 | ALDH1A1 (0.41) | MAPTSMN1; SMN2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16845614 | 0.78 | MAPT (0.52) | MAPTALDH1A1HSD17B10PDE3BPDE3A | |
| SCHEMBL2448392 | 0.77 | ALDH1A1 (0.43) | MAPTCHEK1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14833991 | 0.77 | HDAC6 (0.62) | MAPTSMN1; SMN2CYP2D6ALDH1A1PDE3B | |
| SCHEMBL16054935 | 0.75 | MAPT (0.45) | MAPTCHEK1ALOX5SMN1; SMN2CYP1A2 | |
| SCHEMBL8552595 | 0.71 | RAB9A (0.42) | MAPTCHEK1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12634224 | 0.69 | HDAC6 (0.46) | MAPTSMN1; SMN2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL15442916 | 0.69 | MAPT (0.51) | MAPTALOX5SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10485787-B2 | Oral dosage forms of bendamustine and therapeutic use thereof | ASTELLAS DEUTSCHLAND GMBH (DE) | 2019-11-26 | — | — | US | disclosed |
| US-20150258070-A1 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof | ASTELLAS DEUTSCHLAND GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2575784-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | Astellas Deutschland GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2575785-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF | Astellas Deutschland GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2367542-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | Astellas Deutschland GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367538-A2 | SOLID DOSAGE FORMS OF BENDAMUSTINE | Astellas Deutschland GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010063493-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063476-A2 | SOLID DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10485787-B2 | Oral dosage forms of bendamustine and therapeutic use thereof | MCL1, BCL9, BCL9L | MAPT 1545/4885CHEK1 1943/4885ALOX5 438/4885 |
| US-20150258070-A1 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof | MCL1, BCL9, BCL9L | MAPT 1545/4885CHEK1 1943/4885ALOX5 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.